Literature DB >> 1375867

Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease.

H B Carter1, C H Morrell, J D Pearson, L J Brant, C C Plato, E J Metter, D W Chan, J L Fozard, P C Walsh.   

Abstract

Prostate growth curves were estimated from serial prostate-specific antigen (PSA) measurements on frozen sera in three groups of men: (a) 16 men with no prostatic disease by urological history and examination; (b) 20 men with a histological diagnosis of benign prostatic hyperplasia (BPH) who had undergone simple prostatectomy; and (c) 18 men with a histological diagnosis of prostate cancer. The median number of repeated PSA measurements over an 8- to 26-yr period prior to histological diagnosis or exclusion of prostate disease was eight and 11 for noncancer and cancer subjects, respectively. Predicted rates of change in PSA (PSA velocity) were linear and curvilinear for control and BPH subjects, respectively. Subjects with cancer demonstrated both a linear and an exponential phase of PSA velocity. Based on time to double PSA, we estimated the epithelial doubling time for men without prostate disease to range from 54 +/- 13 yr at age 40 to 84 +/- 13 yr at age 70. For men with BPH, doubling times ranged from 2 +/- 13 yr at age 40 to 17 +/- 5 yr at age 85. Subjects with local/regional and advanced/metastatic cancer had similar PSA doubling times of 2.4 +/- 0.6 yr and 1.8 +/- 0.2 yr, respectively. These data are consistent with what is known about prostatic growth with age in men without prostate disease and BPH, and the kinetics of prostate cancer growth. Estimates of prostatic growth rate from changes in PSA may be useful clinically in management of men with prostate disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1375867

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

Review 1.  The role of prostate specific antigen in screening and management of clinically localized prostate cancer.

Authors:  Khurshid Guru; Ashutosh Tewari; Ashok K Hemal; John Wei; Javid Javidan; James Peabody; Mani Menon
Journal:  Int Urol Nephrol       Date:  2003       Impact factor: 2.370

2.  PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy.

Authors:  Giampiero Giovacchini; Maria Picchio; Vincenzo Scattoni; Rita Garcia Parra; Alberto Briganti; Luigi Gianolli; Francesco Montorsi; Cristina Messa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-20       Impact factor: 9.236

Review 3.  Prostate cancer: 5. Diagnostic tools for early detection.

Authors:  P I Karakiewicz; A G Aprikian
Journal:  CMAJ       Date:  1998-11-03       Impact factor: 8.262

4.  Association of obesity and smoking with PSA and PSA velocity in men with prostate cancer.

Authors:  Amit M Algotar; Steven P Stratton; James Ranger-Moore; M Suzanne Stratton; C H Hsu; Frederick R Ahmann; Raymond B Nagle; Patricia A Thompson
Journal:  Am J Mens Health       Date:  2011-05

5.  Prostate-specific antigen in patients with relapsed prostate cancer following endocrine treatment.

Authors:  Y Kubota; H Yanai; I Sasagawa; H Suzuki; T Nakada; O Sugano
Journal:  Int Urol Nephrol       Date:  1996       Impact factor: 2.370

Review 6.  Tumor markers in prostate cancer I: blood-based markers.

Authors:  Shahrokh F Shariat; Axel Semjonow; Hans Lilja; Caroline Savage; Andrew J Vickers; Anders Bjartell
Journal:  Acta Oncol       Date:  2011-06       Impact factor: 4.089

Review 7.  Risk-based prostate cancer screening.

Authors:  Xiaoye Zhu; Peter C Albertsen; Gerald L Andriole; Monique J Roobol; Fritz H Schröder; Andrew J Vickers
Journal:  Eur Urol       Date:  2011-11-24       Impact factor: 20.096

8.  The use of multiphase nonlinear mixed models to define and quantify long-term changes in serum prostate-specific antigen: data from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

Authors:  Azza Shoaibi; Gowtham A Rao; Bo Cai; John Rawl; James R Hébert
Journal:  Ann Epidemiol       Date:  2015-10-28       Impact factor: 3.797

Review 9.  Prostate cancer: diagnosis and staging.

Authors:  Nigel Borley; Mark R Feneley
Journal:  Asian J Androl       Date:  2008-12-01       Impact factor: 3.285

Review 10.  Screening for prostate cancer: an update.

Authors:  Shahrokh F Shariat; Peter T Scardino; Hans Lilja
Journal:  Can J Urol       Date:  2008-12       Impact factor: 1.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.